Jump to content

Iodized oil

From Wikipedia, the free encyclopedia

Iodized oil
Clinical data
Trade namesLipiodol, Ethiodol, Vividol
Other namesethiodized oil, ethyl esters of iodised fatty acids
AHFS/Drugs.comInternational Drug Names
License data
Routes of
administration		by mouth, injection (IM, intralymphatic, intrauterine, selective hepatic intra-arterial)
ATC code
Legal status
Legal status
Identifiers
CAS Number
ChemSpider
  • none
UNII
ChEMBL
ECHA InfoCard100.122.502 Edit this at Wikidata

Iodized oil, also known as ethiodized oil, brand name Lipiodol, is a medication derived from poppyseed oil and iodine. When given by injection, it is a radio-opaque contrast agent that is used to outline structures in radiological investigations.[2][3] When given orally or by intramuscular injection once or twice a year, it prevents endemic goitre in remote communities.[4] It has an additional use in gastric variceal obliteration as a dilutant that does not affect polymerization of cyanoacrylate.

When used as tissue contrast, iodized oil has a risk of entering the vein and causing embolism in the brain and lungs.[5] There is a boxed warning referring to the risk of embolism.[6] Use as iodine supplementation is recommended in regions where deficiency is common, otherwise it is not recommended.[4] It should not be used for hysterosalpingography in pregnancy.[6]

Iodized oil was first made in 1901 by Marcel Guerbet and Laurent Lafay. Originally used to treat iodine deficiency, it was identified as an effective radiocontrast in 1921 by Sicard and Forestier, before returning as a tool to treat iodine deficiency in goiter eradication campaigns of the 1980s.[7] Under the name "iodine", iodized oil is on the World Health Organization's List of Essential Medicines, in liquid and capsule form.[4][8]

Medical uses

[edit]

Imaging

[edit]

Iodized oil is a radio-opaque contrast agent. It is used in chemoembolization applications as a contrast agent in follow-up imaging.[9] Lipiodol is also used in lymphangiography, the imaging of the lymphatic system.[10]

Historically Lipiodol was often used as a contrast medium at hysterosalpingography (HSG: a procedure to determine tubal patency [i.e. whether the fallopian tubes are open], used in the investigation of subfertility). It became less commonly utilized in the 1960s to 1980s because the more modern water-soluble media give images that are easier to interpret. There is also an important safety issue with Lipiodol in that intravasation (leakage) of the fluid into the venous system has caused complications in the past.[11]

Chemoembolization

[edit]

Lipiodol is used in conventional transcatheter arterial chemoembolization (TACE), a procedure for treating liver tumors. An anticancer drug is first emulsified into lipiodol to form a suspension. Guided by an imaging system, a catheter is moved into an artery that feeds the tumor and injects the suspension. Lipiodol helps retain the drug around the cancer cells. An embolic material is then injected to restrict blood supply to the tumor.[12]

"Transarterial radioembolization" (TARE) is a similar procedure where the anticancer drug is radioactive. An experimental version of TARE uses iodine-131-labeled lipiodol. The radioactive lipiodol is attracted to the tumor, much like regular lipiodol. Its radioactivity destroys tumor tissue.[13] However, I131-lipiodol has been withdrawn from the market by its European manufacturer due to risk of embolism, especially in patients with hepatic arterio-venous shunting.[14] I131-lipidol is also less tumor-targeted than the microbeads used in conventional TARE procedures, requiring much higher radiation doses.[15] It remains available in India, where its cost-effectiveness over conventional Y90 TARE is valued.[16]

Gastric variceal obliteration

[edit]

It has an additional use in gastric variceal obliteration as a dilutant that does not affect polymerization of cyanoacrylate.

Fallopian tube flushing

[edit]

Since the 2000s, a small number of studies have suggested that flushing lipiodol through the fallopian tubes (similar to what is done in HSG, but without imaging) might provide a short-term rise in fecundity in patients with unexplained infertility. This procedure is called Lipiodol flushing or more broadly tubal flushing. A 2005 systematic review has suggested a significant increase in fertility, especially in those women who have endometriosis when using Lipiodol flushing.[11] A 2020 Cochrane review suggests that flushing with oil-soluble contrast media such as lipiodol may increase the chance of live birth and clinical pregnancy.[17]

Iodine deficiency

[edit]

Lipiodol is given once or twice yearly to remote communities at risk of endemic goitre.[4] The oil can be taken orally or injected intermuscularly. There is also an oral capsule that contains the oil, equivalent to 190 mg iodine.[18][19]

Iodized poppyseed oil (Lipiodol) given orally or intermuscularly produces a long-lasting store of iodine in the body, allowing very infrequent dosing. Iodized oil is a cost-effective way of combating iodine deficiency. There seems to be a lower risk of initial hyperthyroidism compared to iodized salt.[20] Beyond poppyseed oil, locally-available rapeseed (Brassiodol), peanut, walnut, and soybean oils[21] have also been used for producing iodized oil for oral use. These iodized oils have different pharmacological profiles, but have also proven successful in eradicating goiter at a lower cost.[20] In fact, iodized rapeseed and peanut oils provide longer-lasting protection from goiter compared to Lipiodol.[22][23]

Chemistry

[edit]

Ethiodized oil is composed of iodine reacted with ethyl esters of fatty acids of poppyseed oil, primarily as ethyl monoiodostearate and ethyl diiodostearate. One method to produce the oil involves turning iodine into anhydrous hydroiodic acid using silylated reagents, then reacting the acid with fatty acid ethyl esters. Sufficient amounts of the acid is used to ensure that all double bonds are iodinated. The product is washed and purified to remove any free elemental iodine and other organic compounds, leaving only the iodinated esters.[22]

History

[edit]

Lipiodol was first synthesized by Marcel Guerbet in the Paris School of Pharmacy in 1901. It was originally used to treat iodine deficiency.[7]

Historically, Lipiodol was the first iodinated contrast agent (used for myelography by two French physicians, Jacques Forestier and Jean Sicard in 1921).[7] It was first used for lymphography in 1960 as a replacement for the earlier water-soluble contrasts, which quickly diffused outside the lymphatic network and prevented visualization beyond the first few nodes. A transesterified version, Lipiodol Ultra Fluide, was proposed by Wallace specifically for this purpose in 1960.[7]: 168  In 1981, Japanese professor Konno found that when Lipidol is injected into the hepatic artery of patients with hepatocarcinoma, the oily substance is selectively retained by the tumor for several months. He mixed Lipidol with a new drug SMANCS to selectively target cancer cells; thus, chemoembolization was born.[7]: 168 

The use of Lipiodol against iodine deficiency was revived in 1957 by Mac Cullagh, who used it in Papua New Guinea to fight endemic goitre via intramuscular injection. The technique received increasing approval and refinement as a supplement to salt iodization from the Pan American Health Organisation, UNICEF, and WHO. In 1989, it was added to the WHO Model List of Essential Medications.[7]: 169 

Supply status

[edit]

Savage Laboratories supplied thiodized oil for interventional procedure under the brand name "Ethiodol" to the US market until 2011, when the product was discontinued. The Ethiodol product is equivalent to Lipiodol Ultra Fluide.[24]

Ethiodized oil for interventional procedure was solely produced and marketed by Guerbet, until Vivere Imaging launched its oil under the brand name "Vividol" in 2022.

References

[edit]
  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. ^ Ahrar K, Gupta S (January 2003). "Hepatic artery embolization for hepatocellular carcinoma: technique, patient selection, and outcomes". Surgical Oncology Clinics of North America. 12 (1): 105–126. doi:10.1016/s1055-3207(02)00089-3. PMID 12735133.
  3. ^ Sato T (April 2002). "Locoregional immuno(bio)therapy for liver metastases". Seminars in Oncology. 29 (2): 160–167. doi:10.1053/sonc.2002.31716. PMID 11951214.
  4. ^ a b c d World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 499. hdl:10665/44053. ISBN 9789241547659.
  5. ^ Gomi T, Hasegawa M (2012). "Radiological contrast agents and radiopharmaceuticals". Side Effects of Drugs Annual. 34: 749–760. doi:10.1016/b978-0-444-59499-0.00046-5. ISBN 978-0-444-59499-0.
  6. ^ a b "DailyMed - LIPIODOL- ethiodized oil injection". dailymed.nlm.nih.gov.
  7. ^ a b c d e f Bonnemain B, Guerbet M (1995). "Histoire du Lipiodol (1901-1994) ou Comment un médicament peut évoluer avec son temps" [The history of Lipiodol (1901-1994) or How a medication may evolve with the times]. Revue d'Histoire de la Pharmacie (in French). 42 (305): 159–170. doi:10.3406/pharm.1995.4238. PMID 11640460.
  8. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  9. ^ Guan YS, Hu Y, Liu Y (June 2006). "Multidetector-row computed tomography in the management of hepatocellular carcinoma with transcatheter arterial chemoembolization". Journal of Gastroenterology and Hepatology. 21 (6): 941–946. doi:10.1111/j.1440-1746.2006.04474.x. PMID 16724976. S2CID 40066693.
  10. ^ Cabanas RM (2000). "The Concept of the Sentinel Lymph Node". Lymphatic Metastasis and Sentinel Lymphonodectomy. Recent Results in Cancer Research. Vol. 157. pp. 109–20. doi:10.1007/978-3-642-57151-0_9. ISBN 978-3-642-63070-5. PMID 10857165.
  11. ^ a b Johnson NP (2005). "A review of the use of lipiodol flushing for unexplained infertility". Treatments in Endocrinology. 4 (4): 233–243. doi:10.2165/00024677-200504040-00004. PMID 16053340. S2CID 25322807.
  12. ^ de Baere T, Arai Y, Lencioni R, Geschwind JF, Rilling W, Salem R, et al. (March 2016). "Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion". CardioVascular and Interventional Radiology. 39 (3): 334–343. doi:10.1007/s00270-015-1208-y. PMID 26390875. S2CID 12719852.
  13. ^ Ahmadzadehfar H, Sabet A, Wilhelm K, Biersack HJ, Risse J (November 2011). "Iodine-131-lipiodol therapy in hepatic tumours". Methods. 55 (3): 246–252. doi:10.1016/j.ymeth.2011.05.003. PMID 21664971.
  14. ^ Andreana L, Isgrò G, Marelli L, Davies N, Yu D, Navalkissoor S, et al. (October 2012). "Treatment of hepatocellular carcinoma (HCC) by intra-arterial infusion of radio-emitter compounds: trans-arterial radio-embolisation of HCC". Cancer Treatment Reviews. 38 (6): 641–649. doi:10.1016/j.ctrv.2011.11.004. PMID 22169503.
  15. ^ Qian Y, Liu Q, Li P, Han Y, Zhang J, Xu J, et al. (February 2021). "Highly Tumor-Specific and Long-Acting Iodine-131 Microbeads for Enhanced Treatment of Hepatocellular Carcinoma with Low-Dose Radio-Chemoembolization". ACS Nano. 15 (2): 2933–2946. doi:10.1021/acsnano.0c09122. PMID 33529007. S2CID 231788293.
  16. ^ Patel A, Subbanna I, Bhargavi V, Swamy S, Kallur KG, Patil S (April 2021). "Transarterial Radioembolization (TARE) with 131 Iodine-Lipiodol for Unresectable Primary Hepatocellular Carcinoma: Experience from a Tertiary Care Center in India". South Asian Journal of Cancer. 10 (2): 81–86. doi:10.1055/s-0041-1731600. PMC 8460342. PMID 34568220.
  17. ^ Wang R, Watson A, Johnson N, Cheung K, Fitzgerald C, Mol BW, et al. (October 2020). "Tubal flushing for subfertility". The Cochrane Database of Systematic Reviews. 2020 (10): CD003718. doi:10.1002/14651858.CD003718.pub5. PMC 9508794. PMID 33053612.
  18. ^ "IODIZED OIL oral | MSF Medical Guidelines". medicalguidelines.msf.org.
  19. ^ Markou KB, Georgopoulos NA, Makri M, Vlasopoulou B, Anastasiou E, Vagenakis GA, et al. (2003). "Improvement of iodine deficiency after iodine supplementation in schoolchildren of Azerbaijan was accompanied by hypo and hyperthyrotropinemia and increased title of thyroid autoantibodies". Journal of Endocrinological Investigation. 26 (2 Suppl): 43–48. PMID 12762640.
  20. ^ a b Wolff J (January 2001). "Physiology and pharmacology of iodized oil in goiter prophylaxis". Medicine. 80 (1): 20–36. doi:10.1097/00005792-200101000-00003. PMID 11204500.
  21. ^ Medeiros-Neto G, Rubio IG (2016). "Iodine-Deficiency Disorders". Endocrinology: Adult and Pediatric. p. 1597. doi:10.1016/B978-0-323-18907-1.00091-3. ISBN 978-0-323-18907-1.
  22. ^ a b Ingenbleek Y, Jung L, Férard G, Bordet F, Goncalves AM, Dechoux L (November 1997). "Iodised rapeseed oil for eradication of severe endemic goitre". Lancet. 350 (9090): 1542–1545. doi:10.1016/s0140-6736(97)02427-6. PMID 9388412. S2CID 93815.
  23. ^ Untoro J, Schultink W, Gross R, West CE, Hautvast JG (March 1998). "Efficacy of different types of iodised oil". Lancet. 351 (9104): 752–753. doi:10.1016/S0140-6736(05)78525-1. PMID 9504541. S2CID 45475444.
  24. ^ Kolbeck KJ (March 2011). "Lipiodol = ethiodol". Journal of Vascular and Interventional Radiology. 22 (3): 419–420. doi:10.1016/j.jvir.2010.10.030. PMID 21277801.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Iodized_oil&oldid=1248175923"